Autologous CD30.CAR-T for Hodgkin's Lymphoma
This trial is testing a new combination therapy for Hodgkin lymphoma that has failed standard treatment. The goal is to see if it is safe and effective.
- Classical Hodgkin's Lymphoma
- Hodgkin's Lymphoma
- Hodgkin's Disease
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the total proposed sample size for this clinical trial?
"The clinical trial is still recruiting patients, as indicated by the information available on clinicaltrials.gov. This study was posted on 7/25/2022 and was updated on 9/27/2022. They are looking for a total of 15 patients that will be split between 5 different sites."
Is this trial being conducted in different states across America?
"This research is being conducted at Baylor College of Medicine (Houston, TX), UNC Lineberger Comprehensive Cancer Center (Chapel Hill, NC), City of Hope National Medical Center (Duarte, CA), and 5 additional locations."
Are there risks associated with Autologous CD30.CAR-T treatment?
"Autologous CD30.CAR-T is still in the early stages of development, as Phase 1 trials only provide limited data on efficacy and safety. Therefore, it received a score of 1."